Work

Figure S10 from RAS(ON) Multiselective Inhibition Drives Antitumor Immunity in Preclinical Models of NRAS-Mutant Melanoma

Year: 2026

Type: other

Abstract: Supplemental Figure 10: Combination of Anti-PD1 + RMC-7977 alters cell interactions and signaling pathways compared to control and monotherapies. (A) Differential number of interactions and differential interaction strength comparing the control, anti-PD1, RMC-7977 and anti-PD1 + RMC-7977 groups. Blue is higher in control and red is higher in the indicated treated group. (B) Information flow for MHC-I, PDL2, PDL1, MHC-II, CXCL and IFN-II signaling pathways comparing control to indicated treated group anti-PD1, RMC-7977 and Anti-PD1 + RMC-7977 groups compared to control. Red represents the control and blue the indicated treated group

DOI: 10.1158/2326-6066.31028342

Authors: Larissa Anastacio Da Costa Carvalho, Nataliya Tovbis Shifrin, Manali S. Phadke, Michael F. Emmons, Ximo Pechuan-Jorge, Felix Mbuga, Oscar E. Ospina, Christopher Chow, Lillian Seu, Olivia L. Rose, Aparna Hegde, Nikhil I. Khushalani, Elsa Quintana, Keiran S.M. Smalley

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W7119513762

Cites:

Cited by:

Related to: